All data are based on the daily closing price as of April 30, 2026
h
Hanmi Pharm. Co.
128940.KO
310.92 USD
-15.64
-4.79%
Overview
Last close
310.92 usd
Market cap
3.94B usd
52 week high
431.89 usd
52 week low
146.58 usd
Target price
378.06 usd
Valuation
P/E
N/A
Forward P/E
N/A
Price/Sales
3.7569
Price/Book Value
4.9006
Enterprise Value
4.30B usd
EV/Revenue
4.1081
EV/EBITDA
19.3075
Key financials
Revenue TTM
1.05B usd
Gross Profit TTM
597.77M usd
EBITDA TTM
218.10M usd
Earnings per Share
N/A usd
Dividend
1.35 usd
Total assets
1.48B usd
Net debt
219.44M usd
About
Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company's products include Gugutams, a urological combination therapy combining two active ingredients: tamsulosin, a treatment for Obstructive Prostatic Growth (OPG), and tadalafil, a treatment for erectile dysfunction (ED). The company has a research collaboration with MEDIC Life Sciences Inc. to identify cancer biomarkers. The company was founded in 1973 and is based in Hwaseong-si, South Korea.